About

About Xuxin (HongKong) Biotechnology Co., Limited Xu Xin (Hong Kong) Biotechnology Co., Ltd. is a high-tech enterprise located in the Hong Kong Science Park, specializing in AI-driven research and development on innovative RNA-targeted therapy. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies. The company possesses a world-first RNA precision editing technology platform, which includes the world's largest ADAR substrate editing library, an RNA fragment excising tool, and the AI-driven ATOMIC platform. These breakthrough innovations provide strong support and assurance for the company's research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.